Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

Drug resistance can notably restrict clinical applications of gefitinib that is a commonly used EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC). The attempts in exploring novel drug targets and reversal strategies are still needed, since gefitinib resistance has no...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yuhong Jiang (Tekijä), Xin Zhuo (Tekijä), Xiujuan Fu (Tekijä), Yue Wu (Tekijä), Canquan Mao (Tekijä)
Aineistotyyppi: Kirja
Julkaistu: Frontiers Media S.A., 2021-04-01T00:00:00Z.
Aiheet:
Linkit:Connect to this object online.
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

Connect to this object online.

3rd Floor Main Library

Saatavuus: 3rd Floor Main Library
Hyllypaikka: A1234.567
Nide 1 Saatavissa